Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

ConclusionsThe 1-year overall survival with nivolumab monotherapy in Japanese patients with glioblastoma met the prespecified efficacy criterion. The safety profile of nivolumab was consistent with that observed in other tumor types.Clinical Trial RegistrationJapicCTI-152967.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research